A Trial to Investigate Relative Bioavailability of Three Different BI 1291583 Formulations Following Oral Administration at Two Dose Levels to Healthy Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Trial Consisting of 2 Parts)
Latest Information Update: 05 Dec 2024
Price :
$35 *
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 02 Dec 2024 Status changed to active, no longer recruiting.
- 11 Oct 2024 New trial record